HALIFAX, Jan. 29, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2013 Annual General and Special Meeting of Shareholders, which was held on January 25th, 2013. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as Directors of the Company. Dr. Michael Sidler, a representative of the Company's majority shareholder, OnSite Lab Holding AG, was also elected.
"We are very pleased to welcome Dr. Sidler to our Board of Directors," said Hermes Chan, CEO and Director, MedMira. "His expertise in investment and technology commercialization in early-stage companies will make a significant contribution to our Board's role in strategic oversight and business execution as we position ourselves for growth in 2013."
Shareholders approved all other matters considered at the meeting including the appointment of Deloitte as the Company's auditors and ratification of the stock option plan.
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. MedMira is the only Canadian company to be awarded US Army contracts for the development of rapid tests for HIV and Hepatitis viruses. The Company's testing solutions provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira is located in Halifax, Nova Scotia, Canada. www.medmira.com.
This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications
Email: [email protected]